This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rao, S. Articles by Palmer, P.A. Search for Related Content PubMed PubMed Citation Articles by Rao, S. Articles by Palmer, P.A.

Phase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced Colorectal Cancer

From the Royal Marsden Hospital, London and Surrey; Southampton General Hospital, Southampton, United Kingdom; Hospital Saint Antoine; Hospital Tenon, Paris, France; Vienna University Medical School, Vienna, Austria; Johnson & Johnson Pharmaceutical Research and Development, Beerse; St Luc University Hospital, Brussels, Belgium; National Oncological Centre, Sofia, Bulgaria; Oncology Institute, Plesi; Oncology Centre, Pardubice, Czech Republic; Medical University, Debrecen, Hungary; Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ

Address reprint requests to David Cunningham, MD, FRCP, Department of Medicine, Royal Marsden Hospital, Downs Rd, Sutton, Surrey SM2 5PT, United Kingdom; e-mail: david.cunningham{at}icr.ac.uk

PURPOSE: To determine whether R115777 improves survival in patients with refractory advanced colorectal cancer (CRC) in a multicenter, double-blind, prospective randomized study.

PATIENTS AND METHODS: Three hundred sixty-eight patients were randomly assigned to R115777 (300 mg twice daily) orally for 21 days every 28 days or placebo in a 2:1 ratio. All patients received best supportive care. The primary end point was overall survival; secondary end points were progression free survival, tumor response, toxicity, and quality of life.

RESULTS: The two treatment groups were well balanced for baseline demographics, including previous chemotherapy for advanced CRC. The median overall survival for R115777 was 174 days (95% CI, 157 to 198 days), and 185 days (95% CI, 158 to 238 days) for those patients receiving placebo (P = .376). One patient achieved a partial response in the R115777 arm. Stable disease (> 3 months) was observed in 24.3% patients in the R115777 group compared to 12.8% in the placebo arm. This did not translate into a statistically significant increase in progression-free survival. Overall, treatment was well tolerated. There was an increased incidence of reversible myelosuppression (neutropenia, thrombocytopenia), rash, and grade 1 to 2 diarrhea in the R115777 arm. There was no statistically significant difference in quality of life between arms.

CONCLUSION: Single agent R115777, given at this dose and schedule, has an acceptable toxicity profile, but does not improve overall survival compared to best supportive care alone in refractory advanced CRC.

Supported by Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				M. Raponi, J. E. Lancet, H. Fan, L. Dossey, G. Lee, I. Gojo, E. J. Feldman, J. Gotlib, L. E. Morris, P. L. Greenberg, et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia Blood, March 1, 2008; 111(5): 2589 - 2596. [Abstract] [Full Text] [PDF]

				J.-L. Harousseau, J. E. Lancet, J. Reiffers, B. Lowenberg, X. Thomas, F. Huguet, P. Fenaux, S. Zhang, W. Rackoff, P. De Porre, et al. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia Blood, June 15, 2007; 109(12): 5151 - 5156. [Abstract] [Full Text] [PDF]

				E. Van Cutsem, M. Peeters, S. Siena, Y. Humblet, A. Hendlisz, B. Neyns, J.-L. Canon, J.-L. Van Laethem, J. Maurel, G. Richardson, et al. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer J. Clin. Oncol., May 1, 2007; 25(13): 1658 - 1664. [Abstract] [Full Text] [PDF]

				M. Raponi, J.-L. Harousseau, J. E. Lancet, B. Lowenberg, R. Stone, Y. Zhang, W. Rackoff, Y. Wang, and D. Atkins Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia Clin. Cancer Res., April 1, 2007; 13(7): 2254 - 2260. [Abstract] [Full Text] [PDF]

				L Gore, S. Holden, R. Cohen, M Morrow, A. Pierson, C. O'Bryant, M Persky, D Gustafson, C Mikule, S Zhang, et al. A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors Ann. Onc., November 1, 2006; 17(11): 1709 - 1717. [Abstract] [Full Text] [PDF]

				W. S. Siegel-Lakhai, M. Crul, P. De Porre, S. Zhang, I. Chang, H. Boot, J. H. Beijnen, and J. H.M. Schellens Clinical and Pharmacologic Study of the Farnesyltransferase Inhibitor Tipifarnib in Cancer Patients With Normal or Mildly or Moderately Impaired Hepatic Function J. Clin. Oncol., October 1, 2006; 24(28): 4558 - 4564. [Abstract] [Full Text] [PDF]

				C.-C. Wang, Y.-P. Liao, P. S. Mischel, K. S. Iwamoto, N. A. Cacalano, and W. H. McBride HDJ-2 as a Target for Radiosensitization of Glioblastoma Multiforme Cells by the Farnesyltransferase Inhibitor R115777 and the Role of the p53/p21 Pathway. Cancer Res., July 1, 2006; 66(13): 6756 - 6762. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky Lately, It Occurs to Me What a Long, Strange Trip It's Been for the Farnesyltransferase Inhibitors J. Clin. Oncol., July 1, 2006; 24(19): 2981 - 2984. [Full Text] [PDF]

				Y. K. Peterson, P. Kelly, C. A. Weinbaum, and P. J. Casey A Novel Protein Geranylgeranyltransferase-I Inhibitor with High Potency, Selectivity, and Cellular Activity J. Biol. Chem., May 5, 2006; 281(18): 12445 - 12450. [Abstract] [Full Text] [PDF]

				R. T. Eastman, F. S. Buckner, K. Yokoyama, M. H. Gelb, and W. C. Van Voorhis Thematic review series: Lipid Posttranslational Modifications. Fighting parasitic disease by blocking protein farnesylation J. Lipid Res., February 1, 2006; 47(2): 233 - 240. [Abstract] [Full Text] [PDF]

				B. C. Widemann, W. L. Salzer, R. J. Arceci, S. M. Blaney, E. Fox, D. End, A. Gillespie, P. Whitcomb, J. S. Palumbo, A. Pitney, et al. Phase I Trial and Pharmacokinetic Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibromas J. Clin. Oncol., January 20, 2006; 24(3): 507 - 516. [Abstract] [Full Text] [PDF]

				A. D. Basso, P. Kirschmeier, and W. R. Bishop Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors J. Lipid Res., January 1, 2006; 47(1): 15 - 31. [Abstract] [Full Text] [PDF]

				S. G. Young, L. G. Fong, and S. Michaelis Thematic Review Series: Lipid Posttranslational Modifications. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis J. Lipid Res., December 1, 2005; 46(12): 2531 - 2558. [Abstract] [Full Text] [PDF]

				S. J. Cohen, R. B. Cohen, and N. J. Meropol Targeting Signal Transduction Pathways in Colorectal Cancer--More Than Skin Deep J. Clin. Oncol., August 10, 2005; 23(23): 5374 - 5385. [Abstract] [Full Text] [PDF]